UPM‑Kymmene Q4 Outlook: Earnings Turn‑Around, ESG Push & Digital Gains
UPM‑Kymmene’s 2025 Q4 outlook: modest EPS turnaround, rising bioproduct revenue and AI‑driven cost cuts amid EU green rules—investors weigh growth vs. raw‑material risk.
5 minutes to read









